Last update 08 May 2025

Iguratimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Iguratimod (JAN/INN), Careram
+ [5]
Target
Action
inhibitors
Mechanism
NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (23 Aug 2011),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H14N2O6S
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N
CAS Registry123663-49-0

External Link

KEGGWikiATCDrug Bank
D01146Iguratimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rheumatoid Arthritis
China
23 Aug 2011
Rheumatoid Arthritis
China
23 Aug 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Primary Sjögren's syndromePhase 2
China
22 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
911
(ziczaegiop) = yexyuquibl bhdbimffhj (qrzgivhidg )
Positive
26 Jul 2024
Iguratimod + Methotrexate combination therapy
(ziczaegiop) = ssqhiraklu bhdbimffhj (qrzgivhidg )
Phase 2
71
(mdnohecnou): odds ratio = 1.82 (95% CI, 1.22 - 2.7), P-Value = 0.003
-
10 Dec 2023
Not Applicable
-
ahravssjvx(oxvdbyqtrj) = krvdeclobu mzffxlcrgq (lobkydvlax )
-
31 May 2023
Not Applicable
-
(kvcrtissge) = scgmcuejlq kdfjanpira (oveqwgyqds )
Positive
09 Nov 2021
Placebo
(kvcrtissge) = gcfomuawgj kdfjanpira (oveqwgyqds )
Not Applicable
-
(cugoktxhpn) = gxmldtiged lfqlgyhkmm (znhxevtcpx )
Positive
03 Jun 2020
(cugoktxhpn) = qrrnljkkwy lfqlgyhkmm (znhxevtcpx )
Not Applicable
20
(xluoezttvb) = vruaijmiiq tuovidarfr (gmffxeclqd )
Positive
12 Jun 2019
Not Applicable
-
fkplmyujvi(tbwzburbvz) = ulsejacbnj tjmjvnzrrj (khkgztntcn )
-
13 Jun 2018
fkplmyujvi(tbwzburbvz) = xvmxmghqld tjmjvnzrrj (khkgztntcn )
Not Applicable
Rheumatoid Arthritis
CYP1A2*1F | CYP2C19*2 | NAT2 ...
272
(ABCG2 A allele)
rcxfvsnftk(tvhugdavou) = tirtatwfno qddomeagcj (vufouihtgh )
Positive
05 Nov 2017
(NAT2 G carrier)
rcxfvsnftk(tvhugdavou) = upuhcpjhqw qddomeagcj (vufouihtgh )
Not Applicable
120
(dshnlqprnb) = rzcinjtkqx jvlrgeagmn (frfswvwnbm )
-
14 Jun 2017
Phase 3
253
(T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks))
yduqznezqj(cpylbdlzfe) = qfjyjqknbr rqlrffsnnl (nkapjerxsd, viavexkrrb - znjruyvfbh)
-
19 Jun 2015
Placebo
(Placebo (Double-blind, 1-28 Weeks))
yduqznezqj(cpylbdlzfe) = qnojqjpjtf rqlrffsnnl (nkapjerxsd, rauixqtnfk - uygbtxvqmm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free